---
share: "true"
BOX:
  - ê°•ì˜ë¡
í•™ê¸°:
  - "08"
ê³¼ëª©:
  - ë‚´ê³¼í•™1
íŒ€í‹°ì¹­: ë‚¨ë‚´
ì°¨ì‹œ: 3ì£¼ì°¨
ì§„í–‰ë¥ : 
tags:
  - 08ì¤‘ê°„
ì§„í–‰ë„: 5%
---

# Treatment of Primary Immune-mediated disease

 

# Principles

- (1) ìê°€ë©´ì—­ì´ ì¼ì–´ë‚˜ì§€ ì•Šë„ë¡, (2) ë©´ì—­ ì–µì œ ì•½ë¬¼ë¡œ ì¸í•œ ë¶€ì‘ìš©ì„ ìµœì†Œí™”í•˜ë„ë¡
  í•˜ëŠ” ê²ƒì´ ì¹˜ë£Œì˜ ì›ì¹™.
- ì•½ë¬¼ ë¶€ì‘ìš©ì´ ê°ìˆ˜ë˜ì–´ì•¼ í•œë‹¤.
- ê°€ëŠ¥í•œ ì²œì²œíˆ ì¤„ì—¬ì•¼ í•œë‹¤.
- ì²˜ìŒ ì•½ì´ íš¨ê³¼ê°€ ì—†ìœ¼ë©´ ë‹¤ë¥¸ ì•½ë¬¼ë¡œì˜ ë³€ê²½ì„ ê³ ë ¤í•œë‹¤.
- ì•½ë¬¼ íš¨ê³¼ì™€ ë¶€ì‘ìš©ì„ ë‘˜ ë‹¤ ì˜ ëª¨ë‹ˆí„°ë§í•œë‹¤. ê°œê°œì¸ì— ë”°ë¼ 

# Overview

- **Glucocorticoid**ì— ì†í•˜ëŠ” `predisone`ê³¼,
- ë¶€ì†(adjunctive) ë©´ì—­ì–µì œì œë“¤ : `Azathioprine`, `Chlorambucil`, `Cyclosporine`, `Vincristine`, `hIVIG`, `Mycophenolate mofetil` (MMF), `Leflunomide`
![[Pasted image 20241015220803.png|600]]

| Drug             | Dose (dog)                                                    |                              |
| ---------------- | ------------------------------------------------------------- | ---------------------------- |
| **Prednisolone** | 2-4 mg/kg/day                                                 |                              |
| **Azathioprine** | 2 mg/kg/day initially,<br>â†’ ê²©ì¼ ë³µìš©ìœ¼ë¡œ ì ì°¨ ê°ì†Œ                     | nucleotide<br>í•©ì„± ë°©í•´          |
| **Chlorambucil** | 0.1-0.2 mg/kg PO q24h initially,<br>â†’ ê²©ì¼ ë³µìš©ìœ¼ë¡œ ì ì°¨ ê°ì†Œ           | ì„¸í¬ë…ì„±/<br>ê³ ì–‘ì´                 |
| **Cyclosporine** | 5-10 mg/kg PO q12-24h,<br>ketoconazole ë³‘ìš© ì‹œ 1.25-5 mg/kg q12h | ì„¸í¬ë…ì„±/<br>ê³ ì–‘ì´                 |
| **Vincristine**  | 0.02 mg/kg IV as a single dose (ITP)                          | í•­ì•”ì œ                          |
| **hIVIG**        | 0.25-1.5 g/kg as an IV infusion, over 6-12h                   |                              |
| **MMF**          | 10 mg/g PO q12h                                               | nucleotide<br>í•©ì„± ë°©í•´          |
| **Leflunomide**  | 2-4 mg/kg PO q24h                                             | nucleotide<br>í•©ì„± ë°©í•´/<br>IMPA |

# ì•½ë¬¼

## 1ï¸âƒ£ Glucocorticoids : Prednisolone, ..

- Effective + Rapid acting + Inexpensive = ğŸ‘
![[Pasted image 20241016003601.png|800]]

- **PDS(prednisolone)** ì´ìš©ì´ 90% ì´ìƒ
- ê°€ëŠ¥í•˜ë©´ **ê²½êµ¬ íˆ¬ì—¬**ê°€ ì´ìƒì , ì£¼ì‚¬ì œë¡œëŠ” dexamethasone ê°€ëŠ¥
- ê¸°ì „ : cytosolic glucocorticoid receptorì— ë¶€ì°©í•˜ì—¬ â†’ í•µìœ¼ë¡œ ì´ë™ â†’ DNAì— ë¶€ì°©í•˜ì—¬ DNA ì „ì‚¬ë¥¼ ë°©í•´
- ì´ˆê¸° íš¨ê³¼ : **ì í˜ˆêµ¬ íƒì‹ ì‘ìš©ì˜ ë°©í•´** (rapid decrease in the phagocytic activity)
- ì¥ê¸° íš¨ê³¼ : **ì„¸í¬ì„± ë©´ì—­ì˜ ì–µì œ** (suppression of cell-mediated immunity)
	- ì„¸í¬ë§‰ì˜ ì•ˆì •í™” | phospholipase A2ì˜ ì–µì œ | cytokine(IL-1, IL-6) ë°©ì¶œ ê°ì†Œ | Fc receptor ë°œí˜„ ê°ì†Œ

>[!info] Prednisolone (> Prednisone)
>- **Intermediate-acting** | **alternate day** (ê²©ì¼ ë³µìš©) | **2-2.2 mg/kg/day PO(=ê²½êµ¬)**
>- Predisoneì´ ê°„ì—ì„œ ëŒ€ì‚¬ë˜ë©´ **prednisolone**. -soloneì˜ ìƒì²´ì´ìš©ë¥ ì´ í›¨ì”¬ ë†’ê³ , êµ­ë‚´ì—ëŠ” -solone ì œì œë§Œ ìˆìŒ.
>- ê³ ì–‘ì´ëŠ” ë” ë†’ì€ ì €í•­ì„±ì„ ê°€ì§.
>	- 2ë°° ìš©ëŸ‰ íˆ¬ì—¬ (2-4 mg/kg/day)
>	- 4 mg/week dexamethasone (í•œ ë²ˆì— ê¸¸ê²Œ but ì˜ ì“°ëŠ” ë°©ë²•ì€ ì•„ë‹˜)
>- Septic shock, ë¶€ì‹  ì§ˆë³‘, í˜¸í¡ê¸° ì§ˆí™˜, ê°„, ìœ„ì¥ê´€, ë©´ì—­ë§¤ê°œì§ˆë³‘, í”¼ë¶€ë³‘, í•­ì•”, ì—¼ì¦ ì™„í™”, ì†Œì–‘ê° ê°ì†Œ ë“± ë‹¤ì–‘í•œ íš¨ê³¼ê°€ ìˆìœ¼ë‚˜, <u>ê°ì—¼ì¼ ë•ŒëŠ” ê¶Œì¥ë˜ì§€ ì•ŠëŠ”ë‹¤</u>.

- ì¥ê¸° ë¶€ì‘ìš© (ìœ„ì¥ê´€ ì¶œí˜ˆì„ ì œì™¸í•˜ë©´ ì¿ ì‹± ì¦ìƒê³¼ ìœ ì‚¬!)
	- í”íˆ polyuria/polydipsia (ë‹¤ìŒë‹¤ë‡¨) | panting | weakness(í—ˆì•½) | dermatologic changes (í”¼ë¶€ ë³€í™”) | predisposition to infection (ê°ì—¼ì— ì·¨ì•½) | gastrointestinal hemorrhage (ìœ„ì¥ê´€ ì¶œí˜ˆ) | muscle atrophy (ê·¼ìœ¡ ìœ„ì¶•)
	- ê·¸ ì™¸ì— insulin resistance (ì¸ìŠë¦° ì €í•­ì„±) | hyperglycemia (ê³ í˜ˆë‹¹ì¦) | vacuolar hepatopathy (ê³µí¬ì„± ê°„ë³‘ì¦) | hypercoagulability (ê³¼ì‘ê³ : TEG(thromboelastography)ë¡œ ê²€ì‚¬)

| ì¥ê¸° ë¶€ì‘ìš©                                   |                                             |
| ---------------------------------------- | ------------------------------------------- |
| **polydipsia/polyuria<br>(ë‹¤ìŒ/ë‹¤ë‡¨)**       | **dermatologic changes<br>(í”¼ë¶€ ë³€í™”)**         |
| **panting<br>(í—¥í—¥ê±°ë¦¼)<br>**                | **predisposition to infection<br>(ê°ì—¼ì— ì·¨ì•½)** |
| **weakness<br>(í—ˆì•½)**                     | **gastrointestinal hemorrhage<br>(ìœ„ì¥ê´€ ì¶œí˜ˆ)** |
| **muscle atrophy<br>(ê·¼ìœ¡ ìœ„ì¶•)**            |                                             |
| hyperglycemia<br>(ê³ í˜ˆë‹¹ì¦)                  | insulin resistance<br>(ì¸ìŠë¦° ì €í•­ì„±)             |
| hypercoagulability<br>(ê³¼ì‘ê³ )<br>: TEGë¡œ ê²€ì‚¬ | vacuolar hepatopathy<br>(ê³µí¬ì„± ê°„ë³‘ì¦)           |

\* TEG : Thromboelastography

\* í˜ˆë‹¹ì„ ë†’ì´ê¸° ë•Œë¬¸ì— ë‹¹ë‡¨ í™˜ìì—ì„œ ì£¼ì˜

<br>

- ë¶€ì‘ìš© ìµœì†Œí™” + íš¨ê³¼ ê·¹ëŒ€í™”ë¥¼ ìœ„í•´
	- ê³ ìš©ëŸ‰(ì •ëŸ‰)ìœ¼ë¡œ ì‹œì‘í•˜ë˜ (high doses initially)
	- ì ì°¨ ì¤„ì—¬ì„œ ì§ˆë³‘ì„ í†µì œí•  ìˆ˜ ìˆëŠ” ìµœì†Œ ìš©ëŸ‰ì— ë„ë‹¬ (lowest dose possible)
	- short-actingì´ ê¶Œì¥ë˜ë©°, alternative-day therapy (ê²©ì¼ íˆ¬ì•½)ì´ ì¢‹ë‹¤.
	- ë‹¨ê¸°ê°„ì— ê¸‰í•˜ê²Œ ì•½ì„ ì¤„ì´ë©´ ì¬ë°œ ìœ„í—˜ì´ ë†’ì•„ì§€ë¯€ë¡œ, ì²œì²œíˆ ì¤„ì´ë„ë¡ í•œë‹¤ (slowly tapered)
	  : í•œ ë‹¬ì— ê¸°ì¡´ ëŒ€ë¹„ 50% ì´ìƒ ì¤„ì´ì§€ ì•Šë„ë¡ í•œë‹¤. (ë³´í†µ 2ì£¼ì— 1ë²ˆ tapering)
- ê³ ì–‘ì´ì—ì„œëŠ” ë¶€ì‘ìš©ì´ ëœí•œ í¸.
- Steroid ì•½ë¬¼ì´ íš¨ê³¼ê°€ ì—†ì„ ê²½ìš° â†’ ë‹¤ë¥¸ ë©´ì—­ì–µì œì œë¥¼ ì‚¬ìš©. ì´ë•Œ ìŠ¤í…Œë¡œì´ë“œ ì•½ë¬¼ì„ í•œ ë²ˆì— ëŠìœ¼ë©´ ì•ˆ ë¨(ì²´ë‚´ í•©ì„±ëŸ‰ ì¤„ì–´ë“  ìƒíƒœ), ì ì°¨ ì¤„ì´ë˜ ë¹ ë¥´ê²Œ í•œë‹¤.

## 2ï¸âƒ£ Azathioprine

- 2ì„  ì•½ë¬¼ë¡œ ìì£¼ ì„ íƒë¨.

## 3ï¸âƒ£ Chlorambucil

## 4ï¸âƒ£ Cyclosporine

---

## 5ï¸âƒ£ Mycophenolate mofetil

## 6ï¸âƒ£ Splenectomy

## 7ï¸âƒ£ Human intravenous Immunoglobulin

## 8ï¸âƒ£ Pentoxifylline

## 9ï¸âƒ£ Vincristine